Compare C3.ai Inc (AI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Novartis AG — how do they compare? C3.ai Inc trades at $10.58 (market cap $1.59B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 187.5× C3.ai Inc's market cap, and Novartis AG pays a 3.02% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | NVS | |
|---|---|---|
Market Cap | $1.59B | $298.18B |
Sector | Technology | Health |
52-Week High | $19.66 | $168.62 |
52-Week Low | $7.76 | $119.31 |
Enterprise Value | $1.02B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.22, up 3.65% with a bullish technical signal. The company shows revenue growth to $389M in 2025 but continues significant losses with a -187.95% net income margin. Recent recognition as a leader in AI platforms by Forrester Research (August 10, 2026) provides positive momentum, though cash flow remains negative. Analyst consensus is mixed with 21% buy ratings and a $10.20 price target slightly below current levels.
The outlook remains challenging with persistent losses offset by strong market positioning in enterprise AI. Investment opportunity lies in the company's leadership recognition and sector growth potential, while risks include unsustainable cash burn and competitive pressures. The stock faces near-term resistance at $11 with support at $10.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
